CAMBRIDGE, Mass., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share, for total gross proceeds of approximately $125,000,000. In addition, the underwriters have a 30-day option to purchase up to 1,171,875 additional shares of common stock at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on January 26, 2018 under the symbol “SLDB.” The offering is expected to close on January 30, 2018, subject to customary closing conditions.
J.P. Morgan, Goldman Sachs & Co. LLC and Leerink Partners are acting as joint book-running managers for the offering, and Nomura and Chardan are acting as co-managers for the offering.
The offering is made only by means of a prospectus. When available, a copy of the final prospectus relating to this offering may be obtained from:
J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-866-803-9204 or by email: prospectus-eq_fi@jpmchase.com ; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, fax: 212-902-9316, email: prospectusgroup-ny@ny.email.gs.com ; or Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110 or by telephone at (800) 808-7525, ext. 6132 or by email at syndicate@leerink.com .
A registration statement relating to the offering has been filed with, and declared effective by, the United States Securities and Exchange Commission (“SEC”). Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov . This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.
About Solid Biosciences
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Currently, Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. The company’s lead candidate, SGT-001, is an adeno-associated viral (AAV) vector-mediated gene therapy, which is currently under investigation in a Phase I/II clinical trial called IGNITE DMD.
Contact:
Solid Biosciences
Kate Niazi-Sai
617-337-4680
media@solidbio.com
Chris Brinzey
Westwicke Partners
339-970-2843
chris.brinzey@weswicke.com
Source:Solid Biosciences Inc.